Dolby Laboratories
DLB Industrials Specialty Business Services
Dolby Laboratories' revenue for fiscal 2025 (year ended September 2025) was $1.3 billion, up 5.92% from fiscal 2024.
- Revenue
- −3.34%
- EPS
- −37.5%
- Free cash flow
- +157.4%
Quarter to June 2026, against a year earlier
Follow DLB
Alert me
Dolby Laboratories (DLB) valuation and DCF model
At $64.77 the price implies free cash flow after share-based pay growing 7.9% a year for ten years.
Free cash flow after share-based pay grew 16.8% a year over the last ten years, −1.0% over the last five. The price asks for less than its ten-year rate. The industry’s median company is priced for 14.5%.
In September 2017 the price assumed 9.2% a year; Dolby Laboratories went on to grow free cash flow after share-based pay 4.8% a year to FY2025.
- The price needs
- 7.9% a year for ten years
- $64.77
- today’s price
- Its base case
- 16.8% a year for five years, then 10.1%
- $96.34
- 48.7% above today’s price
Base case on its own ten-year record Dolby Laboratories’s own growth, carried forward
Its assumptions
Powerpack lets you start from a scenario and type over any of them.
How we got there$3.11b 10 years of cash to equity+$5.40b terminal value+$739.54m net cash=$9.25b equity value÷96.01m shares=$96.34 per share
Valuation against its own history
| Multiple | Current | 5Y avg | 10Y avg | vs 10Y avg | Industry median | vs industry | 10Y range |
|---|---|---|---|---|---|---|---|
| P/E | 26.74× | 31.16× | 41.88× | 36% below | 25.69× | 4% above | |
| P/FCF | 16.61× | 21.45× | 23.25× | 29% below | 16.50× | 1% above | |
| P/B | 2.31× | 2.81× | 2.88× | 20% below | 2.31× | 0% above | |
| EV/EBITDA | 15.36× | 18.40× | 17.95× | 14% below | 11.75× | 31% above | |
| EV/Sales | 3.88× | 4.70× | 4.91× | 21% below | 1.57× | 147% above |
DLB trades at 3.88× EV/Sales, against a 10-year average of 4.91× (range 3.88×–5.96×). That is cheaper than 100% of the last 9 year-end readings; re-rating to the average implies $79.92 per share.